Siamab Therapeutics, Inc.

UEI
DJM5GUE2NWD7
CAGE
4AE06
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
siamab.com
Founded
2006
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells HHSN261201600042C National Cancer Institute (NIH) $1,499,399
Other function: specific glycan targeting to eradicate cancer stem cells HHSN261201400027C National Cancer Institute (NIH) $222,319
The purpose of this topic is to develop technologies to characterize glycan moieties of glycoproteins to enhance the… HHSN261200900034C National Cancer Institute (NIH) $799,889
Sbir phase 1 topic 237: gylcan arrays for biomarker discovery and validation HHSN261200700063C National Cancer Institute (NIH) $150,000

Grant awards

Award Agency Obligated Awarded
Lead identification of therapeutic anti-glycan antibodies for cancer therapy R43CA186326 National Institutes of Health $219,846
N-glycolylneuraminic acid in the pathogenesis and progression of rheumatoid arthr R43AR056166 National Institutes of Health $152,526
Detection of non-human sialic acid in biotherapeutic applications R41GM080959 National Institutes of Health $202,116

Quick answers

Is Siamab Therapeutics, Inc. registered in SAM.gov?

Siamab Therapeutics, Inc.'s SAM.gov registration expired on October 11, 2019.

What is Siamab Therapeutics, Inc.'s most recent federal award?

Siamab Therapeutics, Inc.'s most recent federal contract award is Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells (HHSN261201600042C), from National Cancer Institute (NIH), on September 19, 2016.

On GovTribe

See Siamab Therapeutics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login